DEXCOM INC Q3 FY2026 earnings call

• Clinical Evidence & Access Expansion: The CONNECT study, published in the New England Journal of Medicine, demonstrated significant A1c improvements for Type 2 non-insulin patients, providing landmark evidence to support broader Medicare and commercial coverage. Management anticipates CMS to announce Type 2 non-insulin coverage expansion later this year.
• Product Portfolio Advancements: The G7 15-day system is gaining traction in the U.S., with survivability improving by 4-5 points due to updated adhesives. Launches are planned for Canada in November and Japan in early 2027. Additionally, the redesigned Stello app was launched to enhance personalization and data insights.
• Operational Execution & Manufacturing: Gross margins expanded significantly, reaching 65.1%, driven by manufacturing efficiencies, freight cost reductions, and quality improvements. The Ireland facility has commenced commercial production on schedule, expanding global capacity.
• Strategic Leadership Changes: Jereme Sylvain was promoted to Chief Operating Officer in addition to his role as CFO, consolidating oversight of operations, quality, and customer success to align closer with financial and strategic priorities.
• Digital Ecosystem Expansion: DexCom is expanding its digital customer support tools, including 'my DexCom' accounts, into international markets such as Europe and Asia Pacific to improve retention and user experience.

DexCom reported worldwide revenue of $1.34 billion, representing an 11% increase on both a reported and organic basis compared to the third quarter of 2025. The U.S. segment was the primary growth driver, generating $970 million in revenue, a 14% increase from the prior year period, fueled by share gains particularly among Type 2 non-insulin patients. International revenue totaled $375 million, growing 5% on both a reported and organic basis; this slower rate reflects lapping favorable reimbursement wins from the second half of 2025, with management expecting normalization to higher growth levels in early 2027.

• Revenue Guidance: Updated full-year 2026 revenue guidance to $5.20–$5.25 billion, implying 12–13% growth. This revision incorporates Q3 outperformance but accounts for approximately $5 million in incremental foreign exchange headwinds.
• Margin Guidance: Maintained non-GAAP gross profit margin guidance at approximately 64%. Increased non-GAAP operating profit margin guidance to approximately 24% and adjusted EBITDA margin guidance to approximately 32%, reflecting strong operational leverage despite Ireland ramp-up costs.

• Payer Contract Losses: DexCom recently lost a preferred status contract with a major PBM (CVS), affecting less than 4% of U.S. revenue. While management expects minimal financial impact due to potential price increases for non-preferred tiers and access via medical benefits, there is risk of patient disruption.
• International Reimbursement Variability: International growth rates can be volatile due to the timing of reimbursement decisions, creating short-term headwinds or tailwinds that may obscure underlying organic growth trends.
• Competitive Pricing Pressure: Although DexCom reports stable pricing, competitors have cited pricing headwinds in cash-pay markets outside the U.S., posing a potential risk if market conditions deteriorate or if incumbents overprice into new competitive windows.

Q: Analysts asked about category growth debates and competitor claims of pricing headwinds. / A: CEO Jake Leach stated that category demand remains strong, evidenced by record new patient starts and raised guidance. CFO Jereme Sylvain confirmed no significant pricing degradation has been observed in DexCom’s markets, citing stable gross margins as proof that their tiered product portfolio matches reimbursement needs effectively without eroding value.

Q: Questions focused on the impact of a recent PBM formulary loss (CVS) and patient access continuity. / A: Management clarified the loss affects <4% of U.S. revenue. They emphasized that most patients retain access via medical benefits/DME channels. To mitigate disruption, DexCom is launching 'DexCom Direct,' a service to help patients navigate coverage options, though switching to non-preferred tiers may result in significantly higher copays.

Q: Analysts inquired about the timeline for Medicare Type 2 non-insulin coverage and the G8 launch. / A: CEO Leach reaffirmed expectations for a CMS coverage decision later this year, leveraging the newly published CONNECT data which provides Level A evidence. Regarding G8, he noted the team is making excellent progress on accuracy and performance, targeting a launch in late 2027 or early 2028 depending on regulatory timelines.

Q: Queries addressed the financial and operational impact of the new Ireland manufacturing facility. / A: CFO Sylvain explained that while Ireland’s ramp-up will cause a sequential step-down in gross margins in Q4 2026, it is a necessary investment for long-term resilience. He noted that once fully operational, the facility will eliminate startup costs and contribute to margin expansion, alongside the increasing penetration of the higher-margin G7 15-day system.

Q: Discussion centered on the 'Smart Basal' feature and sales force efficiency in the Type 2 non-insulin space. / A: CEO Leach highlighted that Smart Basal helps basal insulin users reach optimal doses quickly without hypoglycemia, driving prescriber satisfaction and share gains. CFO Sylvain added that the sales force is efficiently targeting Primary Care Physicians (PCPs) using customized tools and coverage calculators to maximize limited interaction time with busy physicians.